New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from the proof-of-concept Phase 2 open-label UNITY...

Related Keywords

Canada ,Valencia ,Carabobo ,Venezuela ,Ohio ,United States ,Houston ,Texas ,Ohio State University ,Spring House ,British Columbia ,Boston ,Massachusetts ,Toronto ,Ontario ,Memorial Hermann Hospital ,American ,Katie Shanahan ,Moise Kj Jr ,Katie Abouzahr ,Kennethj Moise Jr ,Bridget Kimmel ,Kenneth Moise ,Janssen Pharmaceutical Companies Of Johnson ,Drug Administration ,Bloomberg ,Fetal Medicine Foundation World Congress ,Janssen Pharmaceutical Companies ,Allo Hope Foundation ,European Medicines Agency ,National Library Of Medicine ,University Of Toronto Fetal Medicine ,Janssen Research Development ,Johnson ,Hematology Am Soc Hematol Educ Program ,Momenta Pharmaceuticals Announces Fast Track Designation ,Fetal Care Center ,Department Of Women Health ,Exchange Commission ,None Of The Janssen Pharmaceutical Companies ,Companies Of Johnson ,Fetal Center At Children Memorial Hermann Hospital ,Comprehensive Fetal Care Center ,Dell Medical School ,Executive Director ,Allo Hope ,Vice President ,Autoantibody Portfolio ,Maternal Fetal Disease Area Leader ,Janssen Research ,Fast Track ,Fetal Center ,Maternal Fetal Medicine ,Toronto Fetal Medicine ,Mount Sinai Hospital ,American Journal ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Pregnant Individuals ,High Risk ,Early Onset Severe Hemolytic Disease ,Oral Presentation ,Transfus Apher ,Drug Designations ,Hemolytic Diseases ,Hemolytic Disease ,Expert Review ,The Janssen Pharmaceutical Companies Of Johnson Amp ,